Skip to main content
Madhuri Koti DVM, MVSc., PhD
 Madhuri Koti
Assistant Professor
Contact Info

Faculty Bio

Ph.DUniversity of Guelph, Canada
M.V.ScIndian Veterinary Research Institute, India

Lab website:

I am a Veterinarian with Ph.D. in Molecular Immunology. Research in my lab is focused on delineating the role of tumor immune microenvironment in cancer progression and treatment response. Our long term goal is to identify genomic correlates of prognostic and predictive immune biomarkers that reflect differential pre-treatment tumour immune contexture. Identification of these biomarkers will inform decisions for individualized treatment approaches, augment design of novel immunomodulatory therapies and enhance response to conventional chemotherapies.

Research Interests

Research in my lab focuses on anti-tumour immunity and treatment response in ovarian and prostate cancers.

Major themes and areas of research: 

  • Role of Type I Interferon  pathways in sensitivity or resistance to chemotherapy in ovarian cancer using cancer cell lines, in vivo mouse models and patient derived material
  • Immuno-genomic studies to delineate genetic correlates of intra-tumour immune diversity and association with intrinsic and acquired resistance to therapy. 
  • Role of cancer cell intrinsic genetic events and their association with distinct immune microenvironment states in prostate cancer
  • Development of improved non-invasive immune monitoring approaches towards their application as prognostic and predictive indicators for personalized treatment approaches in cancer.

Selected Publications

Abdi Ghaffari, Nichole Peterson, Kasra Khalaj, Natasha Vitkin, Andrew Robinson, Julie-Ann Francis, Madhuri Koti*.  STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer. (2018)British Journal of Cancer. DOI 10.1038/s41416-018-0188-5.

Cole Clifford, Natasha Vitkin, Gillian Reid-Schachter, Julie-Ann Francis, Madhuri Koti*.  Multi-omics in high-grade serous ovarian cancer: biomarkers from genome to the immunome. (2018). American Journal of Reproductive Immunology. May 21:e12975. doi: 10.1111/aji.12975PMID: 29781548

Madhuri Koti*, Amanda Shou Xu, Kevin Yi Mi Ren, Kash Visram, Runhan Ren, David Berman, D. Robert Siemens. Tertiary lymphoid structures associate with tumour stage in urothelial bladder cancer. (2017). Bladder Cancer. vol. 3, no. 4, pp. 259-267.

Runhan Ren, Kathrin Tyrishkin, Charles H. Graham, Madhuri Koti, D. Robert Siemens. Comprehensive immune transcriptomic analysis in bladder cancer reveals subtype specific immune gene expression patterns of prognostic relevance. (2017)Oncotarget. Aug 9;8(41):70982-71001.PMID: 29050337

Katrina K. Au, Nichole Peterson, Peter Truesdell, Gillian Reid-Schachter, Kasra Khalaj, Runhan Ren, Julie-Ann Francis, Charles H Graham, Andrew W. Craig and Madhuri Koti*. CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer. (2017). Gynecologic Oncology. Jun;145(3):436-445. PMID: 28318643

Katrina Au, Cécile Le Page, Runhan Ren, Liliane Meunier, Kathrin Tryshkin, Nichole Peterson, Jennifer Kendall-Dupont, Timothy Childs, Julie-Ann Francis, Charles H Graham, Andrew B. Craig, Jeremy A. Squire, Anne-Marie Mes-Masson, and Madhuri Koti*(2016). STAT1 associated intratumoural TH1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer. The Journal of Pathology: Clinical Research. Sep 19;2(4):259-270. PMID: 27917296

Runhan Ren, Madhuri Koti, Thomas Hamilton, Charles H. Graham, Jasmir G. Nayak, Jas Singh, Darrel E. Drachenberg, D. Robert Siemens. A primer on tumour immunology and prostate cancer immunotherapy. (2016). Can Urol Assoc J. 10  (1-2). PMID: 26977209

Madison Black, Ivraym Barsoum, Tiziana Cotechini, Peter Truesdell, D. Robert Siemens, Madhuri Koti, Andrew Craig, Charles Graham. Activation of the PD-1/PD-L1 immune checkpoint confers chemoresistance and promotes tumor metastasis. (2016). Oncotarget. PMID: 26859684

Katrina Au, Juliana Josahikan, Julie-Ann Francis, Jeremy A. Squire, Madhuri Koti*. Current state of biomarkers in ovarian cancer prognosis. (2015). Future Oncology. Dec 11 (23); 3187-95. PMID: 26551891

Madhuri Koti*, Alex Siu, Isabelle Clement, Mallikarjun Bidarimath, Gulisa Turashvilli, Andrew Edwards, Anne-Marie Mes Masson, Jeremy A. Squire. A distinct pre-existing inflammatory tumor microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer. (2015). British Journal of Cancer. March 31; 112, 1215-1222. PMID: 26695556

Barsoum IB, Koti M, Siemens DR, Graham CH. Mechanisms of hypoxia-mediated immune escape in cancer. (2014). Cancer Research. Dec 15;74(24):7185-90. PMID: 25344227.

Madhuri Koti, Surinder S. Saini, Ashish Sachan and Azad K. Kaushik. Engineered Bovine Antibodies in the Development of Novel Therapeutics, Immunomodulators and Vaccines. (2014). Antibodies.  3, 205-214; doi:10.3390/antib3020205.

Jeff W Martin, Susan Chilton-MacNeill, Madhuri Koti, Andre J van Wijnen, Jeremy A Squire, Maria Zielenska. Digital expression profiling identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as potential predictive biomarkers for neo-adjuvant chemotherapy response in paediatric osteosarcoma. (2014). PLoS One.  May 16;9(5). PMID: 24835790.

Koti M, Gooding RJ, Nuin P, Haslehurst A, Crane C, Weberpals J, Childs T, Bryson P, Dharsee M, Evans K, Feilotter HE, Park PC, Squire JA. Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer. (2013). BMC Cancer.  Nov 16;13:549. PMID: 24237932.

Geraci J, Dharsee M, Nuin P, Haslehurst A, Koti M, Feilotter HE, Evans K. Exploring high dimensional data with Butterfly: a novel classification algorithm based on discrete dynamical systems. (2014). Bioinformatics. Mar 1;30(5):712-8. PMID: 24149051.

Haslehurst AM, Koti M, Dharsee M, Nuin P, Evans K, Geraci J, Childs T, Chen J, Li J, Weberpals J, Davey S, Squire J, Park PC, Feilotter H. EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. (2012). BMC Cancer. Mar 19;12:91. PMID: 22429801.

Weberpals JI, Koti M, Squire JA. Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer. (2011). Cancer Genetics.  Oct;204(10):525-35. PMID: 22137482.

Koti M, Kataeva G, Kaushik AK. A single point mutation in framework region 3 of heavy chain affects viral neutralization dynamics of single-chain Fv against bovine herpes virus type 1. (2011). Vaccine.  Oct 19;29(45):7905-12. PMID: 21872632.

Koti M, Kataeva G, Kaushik AK. Novel atypical nucleotide insertions specifically at VH-DH junction generate exceptionally long CDR3H in cattle antibodies. (2010). Molecular Immunology. Jul;47(11-12):2119-28. PMID: 20435350.

Koti M, Farrugia W, Nagy E, Ramsland PA, Kaushik AK. Construction of single-chain Fv with two possible CDR3H conformations but similar inter-molecular forces that neutralize bovine herpesvirus 1. (2010). Molecular Immunology.  Feb;47(5):953-60. PMID: 20006385.

Kaushik AK, Kehrli ME Jr, Kurtz A, Ng S, Koti M, Shojaei F, Saini SS. Somatic hypermutations and isotype restricted exceptionally long CDR3H contribute to antibody diversification in cattle. (2009). Veterinary Immunology and Immunopathology.  Jan 15;127(1-2):106-13. PMID: 19012969.

Koti M, Kataeva G, Kaushik AK. Organization of D(H)-gene locus is distinct in cattle. (2008). Dev Biol (Basel). ;132:307-13. PMID: 18817318.